The FDA announced on September 19, 2018, that Upsher Smith Laboratories, Inc. voluntarily recalled Bumetanide Tablets, USP, 2 mg, due to failed impurity specifications. The agency classified the recall as Class II.
How to tell if you have it
- Brand: Upsher Smith
- Product: Bumetanide Tablets, USP, 2 mg, 100-count bottle
- NDC: 0832-0542-11
- Lot codes: 372461, 372952, 372954, 372955, 373624, 374539 (Exp 3/31/2020); 375719, 375721, 376684 (Exp 5/31/2020)
- Manufacturer: Upser-Smith Laboratories, LLC, Maple Grove, MN
- Units affected: 29,080 bottles
The hazard
The product is out of specification for an unspecified degradation product. The FDA stated the hazard involves failed impurities and degradation specifications.
Context
GovInfoNow's records show Upsher Smith Laboratories, Inc. has four other recalls on record since November 20, 2012. Other recent recalls of similar products include Sagent Busulfan Injection Recall (May 4, 2026), Macleods Olanzapine Tablets 5mg Recall (August 27, 2026), and Hikma Ramipril Capsules 10mg Recall (August 24, 2026).